Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

FoxO1/Rictor axis induces a nongenetic adaptation to ibrutinib via Akt activation in chronic lymphocytic leukemia

L. Ondrisova, V. Seda, K. Hlavac, P. Pavelkova, E. Hoferkova, G. Chiodin, L. Kostalova, G. Mladonicka Pavlasova, D. Filip, J. Vecera, PF. Zeni, J. Oppelt, Z. Kahounova, R. Vichova, K. Soucek, A. Panovska, K. Plevova, S. Pospisilova, M. Simkovic,...

. 2024 ; 134 (23) : . [pub] 20241022

Language English Country United States

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc25003826

Grant support
R01 CA213442 NCI NIH HHS - United States

Bruton tyrosine kinase (BTK) inhibitor therapy induces peripheral blood lymphocytosis in chronic lymphocytic leukemia (CLL), which lasts for several months. It remains unclear whether nongenetic adaptation mechanisms exist, allowing CLL cells' survival during BTK inhibitor-induced lymphocytosis and/or playing a role in therapy resistance. We show that in approximately 70% of CLL cases, ibrutinib treatment in vivo increases Akt activity above pretherapy levels within several weeks, leading to compensatory CLL cell survival and a more prominent lymphocytosis on therapy. Ibrutinib-induced Akt phosphorylation (pAktS473) is caused by the upregulation of Forkhead box protein O1 (FoxO1) transcription factor, which induces expression of Rictor, an assembly protein for the mTORC2 protein complex that directly phosphorylates Akt at serine 473 (S473). Knockout or inhibition of FoxO1 or Rictor led to a dramatic decrease in Akt phosphorylation and growth disadvantage for malignant B cells in the presence of ibrutinib (or PI3K inhibitor idelalisib) in vitro and in vivo. The FoxO1/Rictor/pAktS473 axis represents an early nongenetic adaptation to B cell receptor (BCR) inhibitor therapy not requiring PI3Kδ or BTK kinase activity. We further demonstrate that FoxO1 can be targeted therapeutically and its inhibition induces CLL cells' apoptosis alone or in combination with BTK inhibitors (ibrutinib, acalabrutinib, pirtobrutinib) and blocks their proliferation triggered by T cell factors (CD40L, IL-4, and IL-21).

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25003826
003      
CZ-PrNML
005      
20250206104726.0
007      
ta
008      
250121s2024 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1172/JCI173770 $2 doi
035    __
$a (PubMed)39436708
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Ondrisova, Laura $u Molecular Medicine, CEITEC Masaryk University, Brno, Czechia $u Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czechia
245    10
$a FoxO1/Rictor axis induces a nongenetic adaptation to ibrutinib via Akt activation in chronic lymphocytic leukemia / $c L. Ondrisova, V. Seda, K. Hlavac, P. Pavelkova, E. Hoferkova, G. Chiodin, L. Kostalova, G. Mladonicka Pavlasova, D. Filip, J. Vecera, PF. Zeni, J. Oppelt, Z. Kahounova, R. Vichova, K. Soucek, A. Panovska, K. Plevova, S. Pospisilova, M. Simkovic, F. Vrbacky, D. Lysak, SM. Fernandes, MS. Davids, A. Maiques-Diaz, S. Charalampopoulou, JI. Martin-Subero, JR. Brown, M. Doubek, F. Forconi, J. Mayer, M. Mraz
520    9_
$a Bruton tyrosine kinase (BTK) inhibitor therapy induces peripheral blood lymphocytosis in chronic lymphocytic leukemia (CLL), which lasts for several months. It remains unclear whether nongenetic adaptation mechanisms exist, allowing CLL cells' survival during BTK inhibitor-induced lymphocytosis and/or playing a role in therapy resistance. We show that in approximately 70% of CLL cases, ibrutinib treatment in vivo increases Akt activity above pretherapy levels within several weeks, leading to compensatory CLL cell survival and a more prominent lymphocytosis on therapy. Ibrutinib-induced Akt phosphorylation (pAktS473) is caused by the upregulation of Forkhead box protein O1 (FoxO1) transcription factor, which induces expression of Rictor, an assembly protein for the mTORC2 protein complex that directly phosphorylates Akt at serine 473 (S473). Knockout or inhibition of FoxO1 or Rictor led to a dramatic decrease in Akt phosphorylation and growth disadvantage for malignant B cells in the presence of ibrutinib (or PI3K inhibitor idelalisib) in vitro and in vivo. The FoxO1/Rictor/pAktS473 axis represents an early nongenetic adaptation to B cell receptor (BCR) inhibitor therapy not requiring PI3Kδ or BTK kinase activity. We further demonstrate that FoxO1 can be targeted therapeutically and its inhibition induces CLL cells' apoptosis alone or in combination with BTK inhibitors (ibrutinib, acalabrutinib, pirtobrutinib) and blocks their proliferation triggered by T cell factors (CD40L, IL-4, and IL-21).
650    12
$a chronická lymfatická leukemie $x farmakoterapie $x metabolismus $x genetika $x patologie $7 D015451
650    12
$a adenin $x analogy a deriváty $x farmakologie $7 D000225
650    12
$a piperidiny $x farmakologie $7 D010880
650    _2
$a lidé $7 D006801
650    12
$a forkhead box protein O1 $x metabolismus $x genetika $7 D000071161
650    12
$a pyrimidiny $x farmakologie $7 D011743
650    12
$a protoonkogenní proteiny c-akt $x metabolismus $x genetika $7 D051057
650    12
$a pyrazoly $x farmakologie $7 D011720
650    _2
$a zvířata $7 D000818
650    12
$a protein RICTOR $x genetika $x metabolismus $7 D000076226
650    _2
$a myši $7 D051379
650    _2
$a proteinkinasa BTK $x metabolismus $x genetika $x antagonisté a inhibitory $7 D000077329
650    _2
$a fosforylace $7 D010766
650    _2
$a nádorové proteiny $x metabolismus $x genetika $7 D009363
650    _2
$a nádorové buněčné linie $7 D045744
655    _2
$a časopisecké články $7 D016428
700    1_
$a Seda, Vaclav $u Molecular Medicine, CEITEC Masaryk University, Brno, Czechia $u Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czechia
700    1_
$a Hlavac, Krystof $u Molecular Medicine, CEITEC Masaryk University, Brno, Czechia $u Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czechia
700    1_
$a Pavelkova, Petra $u Molecular Medicine, CEITEC Masaryk University, Brno, Czechia $u Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czechia
700    1_
$a Hoferkova, Eva $u Molecular Medicine, CEITEC Masaryk University, Brno, Czechia $u Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czechia
700    1_
$a Chiodin, Giorgia $u Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton, United Kingdom
700    1_
$a Kostalova, Lenka $u Molecular Medicine, CEITEC Masaryk University, Brno, Czechia $u Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czechia
700    1_
$a Mladonicka Pavlasova, Gabriela $u Molecular Medicine, CEITEC Masaryk University, Brno, Czechia
700    1_
$a Filip, Daniel $u Molecular Medicine, CEITEC Masaryk University, Brno, Czechia $u Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czechia
700    1_
$a Vecera, Josef $u Molecular Medicine, CEITEC Masaryk University, Brno, Czechia $u Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czechia
700    1_
$a Zeni, Pedro Faria $u Molecular Medicine, CEITEC Masaryk University, Brno, Czechia
700    1_
$a Oppelt, Jan $u Molecular Medicine, CEITEC Masaryk University, Brno, Czechia
700    1_
$a Kahounova, Zuzana $u Department of Cytokinetics, Institute of Biophysics of the Czech Academy of Sciences, Brno, Czechia
700    1_
$a Vichova, Rachel $u Department of Cytokinetics, Institute of Biophysics of the Czech Academy of Sciences, Brno, Czechia
700    1_
$a Soucek, Karel $u Department of Cytokinetics, Institute of Biophysics of the Czech Academy of Sciences, Brno, Czechia
700    1_
$a Panovska, Anna $u Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czechia
700    1_
$a Plevova, Karla $u Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czechia
700    1_
$a Pospisilova, Sarka $u Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czechia
700    1_
$a Simkovic, Martin $u Fourth Department of Internal Medicine-Haematology, University Hospital Hradec Kralove and Faculty of Medicine Hradec Kralove, Charles University, Prague, Czechia
700    1_
$a Vrbacky, Filip $u Fourth Department of Internal Medicine-Haematology, University Hospital Hradec Kralove and Faculty of Medicine Hradec Kralove, Charles University, Prague, Czechia
700    1_
$a Lysak, Daniel $u Department of Haematology and Oncology, University Hospital Pilsen, Pilsen, Czechia
700    1_
$a Fernandes, Stacey M $u Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA
700    1_
$a Davids, Matthew S $u Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA
700    1_
$a Maiques-Diaz, Alba $u Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain
700    1_
$a Charalampopoulou, Stella $u Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain
700    1_
$a Martin-Subero, Jose I $u Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain
700    1_
$a Brown, Jennifer R $u Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA
700    1_
$a Doubek, Michael $u Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czechia
700    1_
$a Forconi, Francesco $u Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton, United Kingdom $u Haematology Department, Cancer Care Directorate, University Hospital Southampton NHS Trust, Southampton, United Kingdom
700    1_
$a Mayer, Jiri $u Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czechia
700    1_
$a Mraz, Marek $u Molecular Medicine, CEITEC Masaryk University, Brno, Czechia $u Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czechia
773    0_
$w MED00002590 $t The Journal of clinical investigation $x 1558-8238 $g Roč. 134, č. 23 (2024)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39436708 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250121 $b ABA008
991    __
$a 20250206104721 $b ABA008
999    __
$a ok $b bmc $g 2263533 $s 1239833
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 134 $c 23 $e 20241022 $i 1558-8238 $m The Journal of clinical investigation $n J Clin Invest $x MED00002590
GRA    __
$a R01 CA213442 $p NCI NIH HHS $2 United States
LZP    __
$a Pubmed-20250121

Find record

Citation metrics

Archiving options